

Protection against the Omicron Variant from Previous S

New England Journal of Medicine

386, 1288-1290

DOI: [10.1056/nejmc2200133](https://doi.org/10.1056/nejmc2200133)

Citation Report

#	ARTICLE	IF	CITATIONS
4	SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environmental Research, 2022, 209, 112911.	3.7	181
5	COVID reinfections surge during Omicron onslaught. Nature, 2022, , .	13.7	22
8	The unnaturalistic fallacy: COVID-19 vaccine mandates should not discriminate against natural immunity. Journal of Medical Ethics, 2022, 48, 371-377.	1.0	22
9	SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers. Vaccines, 2022, 10, 459.	2.1	24
10	Immunity Against the Omicron Variant From Vaccination, Recovery, or Both. Clinical Infectious Diseases, 2022, 75, e672-e674.	2.9	2
13	Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science, 2022, 376, eabn4947.	6.0	651
14	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. New England Journal of Medicine, 2022, 386, 1804-1816.	13.9	311
15	The genomic and clinical features of the COVID-19 Omicron variant: a narrative review. F1000Research, 0, 11, 353.	0.8	1
16	Multiple SARS-CoV-2 Reinfections: A Case Series of Thrice-Infected Individuals. Mayo Clinic Proceedings, 2022, 97, 1021-1023.	1.4	3
20	Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022. Eurosurveillance, 2022, 27, .	3.9	23
21	Proposal of a population wide genome-based testing for Covid-19. Scientific Reports, 2022, 12, 5618.	1.6	5
23	<i>Notes from the Field: </i>SARS-CoV-2 Omicron Variant Infection in 10 Persons Within 90 Days of Previous SARS-CoV-2 Delta Variant Infection â€” Four States, October 2021â€”January 2022. Morbidity and Mortality Weekly Report, 2022, 71, 524-526.	9.0	8
24	Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infectious Diseases, The, 2022, 22, 781-790.	4.6	191
25	There is nothing exempt from the peril of mutation â€” The Omicron spike. Biomedicine and Pharmacotherapy, 2022, 148, 112756.	2.5	11
27	A case of breakthrough infection with SARS-CoV-2 Delta derivative and reinfection with Omicron variant in a fully vaccinated health care professional. Journal of Infection, 2022, 85, e15-e17.	1.7	2
30	Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19â€”Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection â€” United States, June 2021â€”February 2022. Morbidity and Mortality Weekly Report, 2022, 71, 549-555.	9.0	72
31	COVID-19 Infection in Children: Diagnosis and Management. Current Infectious Disease Reports, 2022, 24, 51-62.	1.3	25
33	Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant. Clinical Infectious Diseases, 2022, 75, e361-e367.	2.9	83

#	ARTICLE	IF	CITATIONS
34	Structural and functional impact by SARS-CoV-2 Omicron spike mutations. <i>Cell Reports</i> , 2022, 39, 110729.	2.9	102
35	Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 766-767.	4.6	79
36	New Variants in SARS-CoV-2: What are we Learning from the Omicron Variant?. <i>Archivos De Bronconeumologia</i> , 2022, 58, 3-5.	0.4	2
37	COVID-19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. <i>Microbial Biotechnology</i> , 2022, 15, 1927-1939.	2.0	41
38	The Case for Acquired Immunity as a Strategy to Thwart SARS-CoV-2 Virus Infection. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2022, 41, 51-52.	0.8	0
39	Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	26
40	Overlapping Delta and Omicron Outbreaks During the COVID-19 Pandemic: Dynamic Panel Data Estimates. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e37377.	1.2	2
41	SARS-CoV-2 Omicron Variant in Croatia – Rapid Detection of the First Case and Cross-Border Spread. <i>Pathogens</i> , 2022, 11, 511.	1.2	4
43	Induction of High Neutralizing Activity Against Both Omicron BA.2 and Omicron BA.1 by Coronavirus Disease 2019 Messenger RNA Booster Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1481-1483.	1.9	5
45	SARS-CoV-2 Omicron variant: recent progress and future perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 141.	7.1	315
47	Prior SARS-CoV-2 infection balances immune responses triggered by four EMA-approved COVID-19 vaccines: An observational study. <i>Clinical and Translational Medicine</i> , 2022, 12, e869.	1.7	2
48	SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. <i>Cell Host and Microbe</i> , 2022, 30, 1103-1111.e6.	5.1	38
49	SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. <i>Cell Reports Medicine</i> , 2022, 3, 100651.	3.3	24
50	Omicron SARS-CoV-2 variant of concern. <i>Medicine (United States)</i> , 2022, 101, e29165.	0.4	59
51	Is it really time to ditch the mask?. <i>BMJ</i> , The, 2022, 377, o1186.	3.0	1
52	Risk and protective factors for SARS-CoV-2 reinfections, surveillance data, Italy, August 2021 to March 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	18
54	Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. <i>Nature Medicine</i> , 2022, 28, 1377-1380.	15.2	65
56	Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study. <i>EClinicalMedicine</i> , 2022, 48, 101455.	3.2	49

#	ARTICLE	IF	CITATIONS
57	Determinants of Spike Infectivity, Processing and Neutralization in SARS-CoV-2 Omicron Subvariants BA.1 and BA.2. SSRN Electronic Journal, 0, , .	0.4	0
58	Vaccine mandates for healthcare workers beyond COVID-19. Journal of Medical Ethics, 2023, 49, 211-220.	1.0	18
60	COVID-19 2022 update: transition of the pandemic to the endemic phase. Human Genomics, 2022, 16, .	1.4	68
61	Correlates of protection against <scp>SARS</scp>â€œ<scp>CoV</scp>â€œ infection and COVIDâ€œ19 disease. Immunological Reviews, 2022, 310, 6-26.	2.8	138
63	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nature Communications, 2022, 13, .	5.8	188
64	Risk of SARS-CoV-2 Reinfection by Vaccination Status, Predominant Variant, and Time from Previous Infection: A Cohort Study in Italy. SSRN Electronic Journal, 0, , .	0.4	1
65	Relative Effectiveness of COVID-19 Vaccination with 3 Compared to 2 Doses Against SARS-CoV-2 B.1.1.529 (Omicron) Among an Australian Population with Low Prior Rates of SARS-CoV-2 Infection. SSRN Electronic Journal, 0, , .	0.4	0
66	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. Frontiers in Immunology, 0, 13, .	2.2	7
71	Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. American Journal of Transplantation, 2022, 22, 3130-3136.	2.6	85
72	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. International Journal of Translational Medicine, 2022, 2, 275-308.	0.1	1
73	IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers. Frontiers in Immunology, 0, 13, .	2.2	16
74	OMICRON: Virology, immunopathogenesis, and laboratory diagnosis. Journal of Gene Medicine, 2022, 24, .	1.4	33
75	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. New England Journal of Medicine, 2022, 387, 21-34.	13.9	368
76	Immunological memory to <scp>SARSâ€œCoV</scp>â€œ infection and <scp>COVID</scp>â€œ19 vaccines. Immunological Reviews, 2022, 310, 27-46.	2.8	137
77	SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants. Irish Journal of Medical Science, 2023, 192, 751-756.	0.8	16
79	Expert review on global real-world vaccine effectiveness against SARS-CoV-2. Expert Review of Vaccines, 2022, 21, 1255-1268.	2.0	30
81	Does pre-existing immunity determine the course of SARS-CoV-2 infection in health-care workers? Single-center experience. Infection, 2023, 51, 323-330.	2.3	5
82	A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222. Vaccines, 2022, 10, 914.	2.1	3

#	ARTICLE	IF	CITATIONS
83	Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. <i>Nature Medicine</i> , 2022, 28, 1933-1943.	15.2	243
84	Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, S254-S263.	2.9	15
86	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
87	Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA. <i>Lancet, The</i> , 2022, 400, 535-538.	6.3	27
88	Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7675.	1.8	9
91	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. <i>Cell Host and Microbe</i> , 2022, 30, 1231-1241.e6.	5.1	55
93	“Post-COVID-19 syndrome and humoral response association after one year in vaccinated and unvaccinated patients”: authors' response. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1397-1398.	2.8	6
94	Transient and durable T cell reactivity after COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
96	Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated “VISION Network, 10 States, December 2021” June 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 931-939.	9.0	92
97	Differences in Immunological Evasion of the Delta (B.1.617.2) and Omicron (B.1.1.529) SARS-CoV-2 Variants: A Retrospective Study on the Veneto Region’s Population. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8179.	1.2	6
98	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
99	Intrinsic generation time of the SARS-CoV-2 Omicron variant: An observational study of household transmission. <i>Lancet Regional Health - Europe, The</i> , 2022, 19, 100446.	3.0	34
100	Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. <i>Lancet Regional Health - Europe, The</i> , 2022, 20, 100452.	3.0	37
101	Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study. <i>Lancet Regional Health - Europe, The</i> , 2022, 20, 100453.	3.0	47
102	Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. <i>Reviews in Medical Virology</i> , 2022, 32, .	3.9	276
103	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	1.8	46
105	Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e142-e147.	2.9	8
106	Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2. <i>Cell Host and Microbe</i> , 2022, 30, 1255-1268.e5.	5.1	45

#	ARTICLE	IF	CITATIONS
107	Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron and Delta Related outpatient illness among adults, October 2021 to February 2022. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 975-985.	1.5	11
108	The genomic and clinical features of the COVID-19 Omicron variant: a narrative review. <i>F1000Research</i> , 0, 11, 353.	0.8	0
109	Modelling the Effect of Vaccination and Human Behaviour on the Spread of Epidemic Diseases on Temporal Networks. , 2022, , .		2
110	SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong. <i>Emerging Microbes and Infections</i> , 2022, 11, 2116-2119.	3.0	18
111	Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020 to November 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, S147-S154.	2.9	4
116	Racial/Ethnic Variances in COVID-19 Inoculation among Southern California Healthcare Workers. <i>Vaccines</i> , 2022, 10, 1331.	2.1	1
118	Sub-lineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention. <i>MedComm</i> , 2022, 3, .	3.1	15
120	Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response. <i>Vaccines</i> , 2022, 10, 1281.	2.1	11
121	Vaccines against SARS-CoV-2 variants and future pandemics. <i>Expert Review of Vaccines</i> , 2022, 21, 1363-1376.	2.0	6
122	Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland. <i>JAMA Network Open</i> , 2022, 5, e2225320.	2.8	39
123	Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2022, 380, .	1.6	7
125	SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants. <i>MBio</i> , 2022, 13, .	1.8	6
126	SARS-CoV-2 hybrid immunity: silver bullet or silver lining?. <i>Nature Reviews Immunology</i> , 2022, 22, 591-592.	10.6	41
128	COVID-19 Modeling Outcome versus Reality in Sweden. <i>Viruses</i> , 2022, 14, 1840.	1.5	4
129	Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. <i>Nature Communications</i> , 2022, 13, .	5.8	49
132	How Did the COVID-19 Pandemic Affect Population Mobility in Taiwan?. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10559.	1.2	5
133	Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. <i>Nature Communications</i> , 2022, 13, .	5.8	32
135	Nanotechnology-based strategies against SARS-CoV-2 variants. <i>Nature Nanotechnology</i> , 2022, 17, 1027-1037.	15.6	63

#	ARTICLE	IF	CITATIONS
136	Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern. <i>IScience</i> , 2022, 25, 104935.	1.9	8
137	Immediate reinfection with Omicron variant after clearance of a previous SARS-CoV-2 infection. <i>Journal of Infection and Public Health</i> , 2022, 15, 983-985.	1.9	6
138	Epidemiological assessment of SARS-CoV-2 reinfection. <i>International Journal of Infectious Diseases</i> , 2022, 123, 9-16.	1.5	13
139	Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK). <i>Lancet Regional Health - Europe</i> , The, 2022, 22, 100501.	3.0	9
140	Measuring T-Cell Responses against SARS-CoV-2 Is of Utility for Disease and Vaccination Management. <i>Journal of Clinical Medicine</i> , 2022, 11, 5103.	1.0	5
142	Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era. <i>Cancers</i> , 2022, 14, 4252.	1.7	3
143	Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, .	5.8	8
145	Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers. <i>Vaccine</i> , 2022, 40, 7195-7200.	1.7	17
146	Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 1415.	3.8	76
148	Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
149	COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	10
150	Duration of immune protection of SARS-CoV-2 natural infection against reinfection. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	54
152	Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
153	Long-term Protection Associated With COVID-19 Vaccination and Prior Infection. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 1402.	3.8	13
154	SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study. <i>Viruses</i> , 2022, 14, 1966.	1.5	6
156	Understanding risk factors of a new variant outburst through global analysis of Omicron transmissibility. <i>Environmental Research</i> , 2023, 216, 114446.	3.7	4
157	An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients. <i>ELife</i> , 0, 11, .	2.8	8
158	Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. <i>New England Journal of Medicine</i> , 2022, 387, 1620-1622.	13.9	89

#	ARTICLE	IF	CITATIONS
159	Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection. <i>Vaccine</i> , 2022, 40, 6288-6294.	1.7	17
160	SARS-CoV-2â€™The Role of Natural Immunity: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 6272.	1.0	12
162	Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster. <i>IScience</i> , 2022, 25, 105465.	1.9	2
163	Distinguishing Severe Acute Respiratory Syndrome Coronavirus 2 Persistence and Reinfection: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2023, 76, 850-860.	2.9	3
164	Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 167-176.	4.6	71
165	Neutralizing antibody responses in patients hospitalized with SARS-CoV-2 Delta or Omicron infection. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
166	Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNAâ€™Vaccinated and Nonvaccinated Individuals in Quebec, Canada. <i>JAMA Network Open</i> , 2022, 5, e2236670.	2.8	36
167	CD8+ T-cell immune escape by SARS-CoV-2 variants of concern. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
170	Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	5
173	Immunity Acquired From the First Wave of COVID-19 Against Reinfections Up to Omicron Predominance. <i>Mayo Clinic Proceedings</i> , 2022, , .	1.4	0
174	Rapid SARS-CoV-2 Variants Enzymatic Detection (SAVED) by CRISPR-Cas12a. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	7
175	Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e944-e955.	3.4	34
176	A Tale of 2 mRNA Vaccines. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1909-1911.	1.2	0
177	Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerlandâ€™A multicentre cohort study. <i>PLoS Medicine</i> , 2022, 19, e1004125.	3.9	11
178	Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection. <i>Viruses</i> , 2022, 14, 2458.	1.5	8
179	Persistence of neutralizing antibodies and clinical protection up to 12 months after SARS-CoV-2 infection in elderly. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	0
180	Acute and postacute sequelae associated with SARS-CoV-2 reinfection. <i>Nature Medicine</i> , 2022, 28, 2398-2405.	15.2	241
181	SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta. <i>Science Advances</i> , 2022, 8, .	4.7	28

#	ARTICLE	IF	CITATIONS
183	Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5â€“11 Years. <i>Vaccines</i> , 2022, 10, 1954.	2.1	3
184	Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United Statesâ€“October 25, 2020â€“February 26, 2022. <i>The Lancet Regional Health Americas</i> , 2023, 18, 100403.	1.5	10
186	Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infectionâ€“Final Update of a Living, Rapid Review. <i>Annals of Internal Medicine</i> , 2023, 176, 85-91.	2.0	6
187	Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .	0.6	1
189	A COVID-19 model incorporating variants, vaccination, waning immunity, and population behavior. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
190	Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. <i>PLoS Medicine</i> , 2022, 19, e1004037.	3.9	28
191	Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021â€“March, 2022: a national, observational, test-negative, case-control study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 435-444.	4.6	47
192	Impact of Vaccination, Prior Infection, and Therapy on Omicron Infection and Mortality. <i>Journal of Infectious Diseases</i> , 2023, 227, 970-976.	1.9	6
193	Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity. <i>Vaccine</i> , 2023, 41, 892-902.	1.7	3
195	Time-dependent risk of COVID-19 death with overwhelmed health-care capacity in Japan, 2020â€“2022. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	4
196	B-Cell Responses to Sars-Cov-2 mRNA Vaccines. <i>Pathogens and Immunity</i> , 2022, 7, 93-119.	1.4	0
197	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
198	Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model. <i>Antiviral Research</i> , 2023, 209, 105492.	1.9	6
199	Mandatory vaccinations, the segregation of citizens, and the promotion of inequality in the modern democracy of Greece and other democratic countries in the era of COVID-19. <i>History and Philosophy of the Life Sciences</i> , 2022, 44, .	0.6	2
200	High titre neutralizing antibodies in response to SARSâ€“CoVâ€“2 infection require RBDâ€“specific CD4 T cells that include proliferative memory cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
201	Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination. <i>Vaccines</i> , 2022, 10, 2111.	2.1	1
202	Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. <i>Journal of Infection and Public Health</i> , 2023, 16, 250-256.	1.9	10
203	Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic. <i>Npj Vaccines</i> , 2022, 7, .	2.9	9

#	ARTICLE	IF	CITATIONS
204	Time from last immunity event against infection during Omicron-dominant period in Malaysia. <i>International Journal of Infectious Diseases</i> , 2023, 128, 98-101.	1.5	3
205	Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 2152.	2.1	6
208	Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters. <i>Journal of Virology</i> , 0, , .	1.5	4
209	Current and Emerging Knowledge in COVID-19. <i>Radiology</i> , 2023, 306, .	3.6	30
210	Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. <i>Viruses</i> , 2023, 15, 175.	1.5	33
211	Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals. <i>Oxford Open Immunology</i> , 2023, 4, .	1.2	1
212	Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. <i>Nature Medicine</i> , 2023, 29, 358-365.	15.2	108
213	Protection Conferred by Delta and BA.1/BA.2 Infection Against BA.4/BA.5 Infection and Hospitalization: A Retrospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2023, 227, 800-805.	1.9	3
214	Use of Hu-PBL Mice to Study Pathogenesis of Human-Restricted Viruses. <i>Viruses</i> , 2023, 15, 228.	1.5	3
215	Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2023, 12, 367-387.	1.8	22
216	The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
217	Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi. <i>EClinicalMedicine</i> , 2023, 56, 101800.	3.2	2
218	Omicron. , 2023, , 367-413.		0
219	Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques. <i>JCI Insight</i> , 2023, 8, .	2.3	11
220	A Study on The Efficacy of Vaccination in Elderly Patients with Breakthrough COVID-19 Infection. <i>Korean Journal of Clinical Geriatrics</i> , 2022, 23, 115-122.	0.3	0
221	The Cold-Adapted, Temperature-Sensitive SARS-CoV-2 Strain TS11 Is Attenuated in Syrian Hamsters and a Candidate Attenuated Vaccine. <i>Viruses</i> , 2023, 15, 95.	1.5	8
222	Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily. <i>Healthcare (Switzerland)</i> , 2023, 11, 305.	1.0	3
223	Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines. <i>Biomedicines</i> , 2023, 11, 370.	1.4	15

#	ARTICLE	IF	CITATIONS
224	The disproportionate case-fatality ratio of COVID-19 between countries with the highest vaccination rates and the rest of the world. <i>IJID Regions</i> , 2023, 6, 159-166.	0.5	4
225	How Different Predominant SARS-CoV-2 Variants of Concern Affected Clinical Patterns and Performances of Infected Professional Players during Two Soccer Seasons: An Observational Study from Split, Croatia. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 1950.	1.2	2
226	Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 556-567.	4.6	242
228	COVID-19 Vaccine Effectiveness Against the Omicron Variant in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2023, 118, 664-673.	0.2	3
229	SARS-CoV-2 During Omicron Variant Predominance Among Infants Born to People With SARS-CoV-2. <i>Pediatrics</i> , 0, , .	1.0	0
231	Saliva and Plasma Antibody Levels in Children and Adolescents After Primary Infection With Omicron Variants of SARS-CoV-2 Infection in Germany. <i>JAMA Pediatrics</i> , 2023, 177, 640.	3.3	2
232	Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	1
233	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
234	The impact of COVID-19 on primary health care services in Qatar: 2 years of response and coping 2020-2021. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 7743.	0.3	3
235	Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2. <i>Brain, Behavior, & Immunity - Health</i> , 2023, 28, 100600.	1.3	4
236	Evaluation of COVID-19 vaccines in primary prevention against infections and reduction in severity of illness following the outbreak of SARS-CoV-2 omicron variant in Shanghai. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
237	T Cell Responses to SARS-CoV-2. <i>Annual Review of Immunology</i> , 2023, 41, 343-373.	9.5	48
238	Response to letter entitled: Tixagevimab/cilgavimab pre-exposure prophylaxis and breakthrough infection risk in vaccinated solid organ transplant recipients: Concern for immortal time bias effect. <i>American Journal of Transplantation</i> , 2023, 23, 451-452.	2.6	1
239	Competition of SARS-CoV-2 variants on the pandemic transmission dynamics. <i>Chaos, Solitons and Fractals</i> , 2023, 169, 113193.	2.5	6
240	Viral Mitigation: Weak Theoretical Underpinnings. <i>Studies in Public Choice</i> , 2023, , 9-58.	0.0	0
241	Severity and Outcomes of SARS-CoV-2 Reinfection Compared with Primary Infection: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 3335.	1.2	23
242	Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron. <i>Viruses</i> , 2023, 15, 530.	1.5	1
243	Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance. <i>Journal of Infectious Diseases</i> , 2023, 227, 1348-1363.	1.9	4

#	ARTICLE	IF	CITATIONS
244	Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers. <i>Emerging Infectious Diseases</i> , 2023, 29, 599-604.	2.0	6
245	Features and significance of the recent enormous COVID-19 epidemic in China. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
246	Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty US Navy Sailors and Marines. <i>Journal of Infectious Diseases</i> , 2023, 228, 149-159.	1.9	3
247	Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents. <i>Journal of Pediatrics</i> , 2023, 257, 113371.	0.9	4
248	Maintaining immunological memory to the SARS-CoV-2 virus during COVID-19 pandemic. <i>Russian Journal of Infection and Immunity</i> , 2023, 13, 55-66.	0.2	3
249	Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 816-827.	4.6	35
250	Discussion about the Latest Findings on the Possible Relation between Air Particulate Matter and COVID-19. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 5132.	1.2	4
251	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
254	Curcumin Confers Anti-Inflammatory Effects in Adults Who Recovered from COVID-19 and Were Subsequently Vaccinated: A Randomized Controlled Trial. <i>Nutrients</i> , 2023, 15, 1548.	1.7	5
255	Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England. <i>Nature Communications</i> , 2023, 14, .	5.8	16
256	Two-Year Cohort Study of SARS-CoV-2, Verona, Italy, 2020-2022. <i>Emerging Infectious Diseases</i> , 2023, 29, 822-825.	2.0	0
257	SARS-CoV-2 Variants Show Different Host Cell Proteome Profiles With Delayed Immune Response Activation in Omicron-Infected Cells. <i>Molecular and Cellular Proteomics</i> , 2023, 22, 100537.	2.5	2
258	At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study. <i>Eurosurveillance</i> , 2023, 28, .	3.9	2
259	Humoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients. <i>Vaccines</i> , 2023, 11, 770.	2.1	0
260	Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation. <i>Lancet Microbe</i> , The, 2023, 4, e495-e505.	3.4	3
261	Eight-Month Follow-Up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth Dose. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	0
262	Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	28
263	Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. <i>Clinical Infectious Diseases</i> , 2023, 77, 355-361.	2.9	10

#	ARTICLE	IF	CITATIONS
277	Comparative Analysis of SARS-CoV-2 Variants Across Three Waves in India. , 2023, , 104-118.		0